Skip to main content

Tag: Brexit

Brexit Interrupts Dutch Supply Of Medical Cannabis To British Patients

The new cross Channel “order” splitting the UK from the continent hits cannabis patients first and hard

As was easy to predict, Brexit interrupted vital supplies of medical cannabis (from Holland’s Bedrocan) from reaching British patients. The news hit families on December 15 – less than two weeks before the implementation of new rules and regs. Indeed, the families involved, well used to the need for a highly visible public campaign, made such a stink that the political repercussions are already forcing the government to look for alternatives. 

They are not that hard to find – if you know the industry.

But the question remains, since this was so predictable, why wasn’t this thought about before?

In the short term, at least according to the Independent in the UK who picked up the story after The Guardian broke it, government officials are trying to find solutions and they should not be that hard to find.

Dutch law, however, as some media are reporting, most certainly does not “prohibit” the export of medical cannabis – see Germany right next door.  If that were true, indeed most EU GMP compliant German medical cannabis flos could not have been dispensed via pharmacies so far. 

The process had previously been certified via “issuing British prescriptions” in Holland and having them filled this way.

All the British government actually has to do, in fact, is follow the lead already set by Germany and indeed by Israel in the past. Buy in bulk, flos if necessary, and extract it in the UK. There are already facilities that are being set up to do the same. 

But that kind of thinking, if not process creation is so far sadly absent in just about all things Brexit. Just look at the mess of Channel crossings. Cannabis was always going to be an early victim of the melee.

The question now, among those who work in complex supply chain issues like this all the time – and for many reasons – is how to mend the gap, not only in the short term, but permanently.

Make sure you book your tickets to the International Cannabis Business Conference when it returns to Europe in the summer of 2021!

Would A Successful Brexit Boost The Chances Of British Cannabis Legalization?

It is no secret that the British are in a bit of a constitutional pickle at the moment. How far the country will align itself with the US and outside of the EU is still in play, two weeks out from Halloween. 

One of the stranger vibes in the air, especially after Boris Johnson hired two cannabis reform advocates into his office of late, is the idea that chucking the relationship with the EU and recreational cannabis reform might be linked, if not a good clarion call. 

After all, Aron Banks is no stranger to the CBD call either.

Are people on the British side of the industry seriously advocating Brexit as a way to push forward recreational cannabis reform in the UK? The answer, shockingly, appears to be yes.

Burn It All Down, Baby

For those at the pointed end of the cannabis discussion (namely patients), the debate about how money laundering laws are enforced to target cannabis-themed investments or not within the UK is currently a bit of a cruel joke. For anyone invested or working in the cannabis industry, the continued stutters and starts of the British market is not part of an academic discussion. 

Also, the snail’s pace of British cannabis reform has continued to prove to be too much for just about everyone. 

Who Can Blame The Brits For Wanting Their (Medical) Spice Cake And Eating It Too?

In this environment, it is tempting to just push recreational cannabis reform ideas under the larger ideas of burn, baby, burn which seems to now be in fashion in the geography of Number 10 (Downing Street and official residence of the British Prime Minister).

However, for those who think Brexit is a quick fix – think again.

Start with the fact that the UK is an island nation, and would be required to suddenly grow and source a huge amount of its own food and medicine. Also, the NHS would, as most believe now, simply not survive. Private (American-style) healthcare anyone?

While cannabis might in such circumstances come to be lauded as the wonder drug it is, like a new penicillin for example, does anyone think that bouncing the British economy around to do it under this kind of turbulence is really in the best interests of either patients or recreational consumers that would presumably be shell and wallet shocked?

Deregulation, in other words, and certainly of the kind that seems still to be in the room with a no-deal Brexit, might seem exciting, particularly to those frustrated with the hangover of the prohibition of the past.

However, such strategies are indeed a double-edged sword, both for (certainly) the British economy as well as Britain’s most vulnerable citizens who are cannabis users either “by choice” or through necessity.